An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effectiveness and safety of TMC435 compared
with placebo in participants who are infected with genotype 1 hepatitis C virus who have
never received treatment before. Participants will also receive peginterferon alfa-2a or
peginterferon alfa-2b and ribavirin as part of their treatment.